Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Income (2016 - 2025)

Zevra Therapeutics' Operating Income history spans 11 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Operating Income rose 160.42% year-over-year to $9.3 million; the TTM value through Dec 2025 reached -$62.9 million, up 27.65%, while the annual FY2025 figure was -$62.9 million, 27.65% up from the prior year.
  • Operating Income reached $9.3 million in Q4 2025 per ZVRA's latest filing, up from $4.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $9.3 million in Q4 2025 to a low of -$71.0 million in Q2 2025.
  • Average Operating Income over 5 years is -$10.1 million, with a median of -$5.8 million recorded in 2023.
  • Peak YoY movement for Operating Income: surged 284.37% in 2021, then tumbled 12925.0% in 2023.
  • A 5-year view of Operating Income shows it stood at -$2.8 million in 2021, then plummeted by 221.67% to -$9.1 million in 2022, then crashed by 65.8% to -$15.2 million in 2023, then decreased by 1.71% to -$15.4 million in 2024, then surged by 160.42% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Operating Income are $9.3 million (Q4 2025), $4.1 million (Q3 2025), and -$71.0 million (Q2 2025).